Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Oculis (OCS) announced the publication of a notification of transactions by a person discharging managerial responsibilities.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Oculis (OCS) announced the publication of a notification of transactions by a person discharging managerial responsibilities. The attached notification concerns the purchase of ordinary shares by a member of the company’s Executive Committee on June 10, 2026.
Details
News Market Reaction – OCS
On Jun 16, the first trading day after this news, OCS closed 1.38% below the previous close.
Data tracked by StockTitan Argus for the Jun 16 session.
Historical Context
-
Announcement of Privosegtor presentation at Clinical Trials at the Summit 2026.
-
RSU vesting and settlement for directors including Arshad Khanani and Riad Sherif.
-
Notification of ordinary share purchase by an Executive Committee and Board member.
-
First patient randomized in PREDICT-1 registrational trial of Licaminlimab in dry eye.
-
Participation in Goldman Sachs Global Healthcare Conference to discuss late-stage assets.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
persons discharging managerial responsibilities regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
ZUG, Switzerland, June 15, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the purchase of ordinary shares by a member of the Company’s Executive Committee.
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.